Top 5 Oil Stocks To Invest In Right Now

tags:MMP,WPZ,COP,WLL,RRC,

November 30, 2017: The S&P 500 closed up 0.8% at 2,647.55. The DJIA closed up 1.4% at 24,272.56. Separately, the Nasdaq was up 0.7% at 6,873.97.

Thursday was an absolutely incredible day for broad�U.S. markets. The Dow again cruised to new highs closing above the 24,000 mark for the first time ever and the S&P 500 hit a new all-time high as well. Crude oil started out positive but faded over the course of the day. The S&P 500 sectors were practically all positive in the session. The best performing sectors were consumer staples, industrials, and energy, up 0.9%, 1.6% and 1.5%, respectively. The worst performing sector was real estate up only 0.1%.

Crude oil was relatively flat at $57.28.

Gold was down 0.7% at $1,277.70.

The S&P 500 stock posting the largest daily percentage loss ahead of the close Thursday was Juniper Networks, Inc. (NYSE: JNPR) which traded down about 6% at $27.76. The stock��s 52-week range is $23.87 to $30.96. Volume was 32 million versus the daily average of 5.7 million shares.

Top 5 Oil Stocks To Invest In Right Now: Magellan Midstream Partners L.P.(MMP)

Advisors' Opinion:

• [By John Bromels]

  Magellan Midstream Partners�(NYSE:MMP),�Royal Dutch Shell�(NYSE:RDS-A)(NYSE:RDS-B), and�Darling Ingredients�(NYSE:DAR)�are three energy industry companies that are safe bets to buy and then forget about all summer long.�

• [By Motley Fool Staff]

  Magellan Midstream Partners (NYSE:MMP) Q1 2018 Earnings Conference CallMay. 3, 2018 1:30 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Matthew DiLallo]

  In the meantime, Magellan Midstream Partners (NYSE:MMP) is working on a 600,000 BPD pipeline in the region that could be in service by the middle of next year. Magellan is currently evaluating other options such as a joint venture that could optimize the project, which might shift the time frame and scale of the project. In addition, Magellan is eyeing a potential oil export dock in Corpus Christi, Texas, which it sees as an ideal landing spot for crude coming out of the Permian. The up-to-$700 million project could be up and running by 2020 and give Permian producers access to higher global oil prices. Projects like those potentially position Magellan to continue increasing its 5.4%-yielding distribution at a mid-single-digit annual rate for the next several years.

• [By Reuben Gregg Brewer, Travis Hoium, and Chuck Saletta]

  Often a high yield is an indication of a stock that's facing some sort of trouble -- but not always. If you take the time, you can find high-yield stocks worth buying if you look in the right places. For example, decidedly low-tech�Lamar Advertising Company (NASDAQ:LAMR), beaten-up midstream player�Magellan Midstream Partners, LP�(NYSE:MMP), and renewable power-focused TerraForm Power, Inc. (NASDAQ:TERP) come from vastly different industries. However, each of these high-yield stocks has a solid business and good growth prospects.

Top 5 Oil Stocks To Invest In Right Now: Williams Partners L.P.(WPZ)

Advisors' Opinion:

• [By Dan Caplinger]

  The stock market stayed in a pretty narrow range on Thursday, climbing early in the session but then slowly drifting lower through the afternoon hours. In the absence of major news, investors largely looked forward to key events like trade negotiations among the world's largest economies. Other financial markets saw mixed moves as well, with 10-year Treasury yields climbing above 3.1% while oil prices stayed comfortably above $70 per barrel. Despite the quiet day, some companies had good news that pushed their shares sharply higher. World Wrestling Entertainment (NYSE:WWE), Chesapeake Energy (NYSE:CHK), and Williams Partners (NYSE:WPZ) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well.

• [By Shane Hupp]

  SG Americas Securities LLC lowered its holdings in Williams Pipeline Partners LP (NYSE:WPZ) by 27.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 37,682 shares of the pipeline company’s stock after selling 14,458 shares during the quarter. SG Americas Securities LLC’s holdings in Williams Pipeline Partners were worth $1,297,000 at the end of the most recent reporting period.

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Williams Partners (WPZ)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Reuben Gregg Brewer]

  There's an interesting dichotomy here, however. Crestwood was looking to stay financially disciplined, but it also needed to invest to grow. Doing both at the same time is difficult, which is why it partnered up with Con Ed in the Marcellus region, Shell Midstream Partners LP (NYSE:SHLX) and First Reserve in the Delaware Basin, and Williams Partners (NYSE:WPZ) in the Powder River basin. These agreements allow Crestwood to keep expanding its business without having to foot the entire bill for the investments.

Top 5 Oil Stocks To Invest In Right Now: ConocoPhillips(COP)

Advisors' Opinion:

• [By Matthew DiLallo]

  Oil prices have been on fire over the past year and recently topped $70 a barrel, which is the highest crude has been since late 2014. That rally in the oil market has helped fuel big-time gains in many oil stocks. Three that stand out are Anadarko Petroleum (NYSE:APC), Hess (NYSE:HES), and ConocoPhillips (NYSE:COP) because each has risen more than 20% this year. They might still have additional upside from here given that all three plan on spending billions of dollars to buy back more of their stock.

• [By Chris Lange]

  The number of ConocoPhillips (NYSE: COP) shares short decreased to 23.15 million from the previous level of 24.60 million. Shares were trading at $52.55, within a 52-week range of $42.27 to $61.32.

• [By Rich Smith]

  And yet, a funny thing has been happening in the market for oil stocks over this past week. All of a sudden, Wall Street analysts are talking up free cash flow as a reason to buy oil stocks. In fact, they can't seem to shut up about it. Over just the past few days, I've seen free cash flow mentioned prominently in the analyses of Wall Street bankers on no fewer than three separate oil stocks: ExxonMobil, Chevron (NYSE:CVX), and ConocoPhillips (NYSE:COP).

Top 5 Oil Stocks To Invest In Right Now: Whiting Petroleum Corporation(WLL)

Advisors' Opinion:

• [By Joseph Griffin]

  Whiting Petroleum Co. (NYSE:WLL) – Equities research analysts at Piper Jaffray Companies lifted their Q2 2018 earnings estimates for Whiting Petroleum in a research note issued on Sunday, May 20th. Piper Jaffray Companies analyst K. Harrison now forecasts that the oil and gas exploration company will earn $0.85 per share for the quarter, up from their previous forecast of $0.33. Piper Jaffray Companies currently has a “Hold” rating and a $46.00 target price on the stock. Piper Jaffray Companies also issued estimates for Whiting Petroleum’s Q3 2018 earnings at $0.97 EPS, Q4 2018 earnings at $1.16 EPS, FY2018 earnings at $3.90 EPS, Q1 2019 earnings at $1.70 EPS, Q2 2019 earnings at $1.48 EPS, Q3 2019 earnings at $1.47 EPS, Q4 2019 earnings at $1.59 EPS and FY2019 earnings at $6.24 EPS.

• [By WWW.GURUFOCUS.COM]

  For the details of DFT Energy LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=DFT+Energy+LP

  These are the top 5 holdings of DFT Energy LPWhiting Petroleum Corp (WLL) - 400,000 shares, 18.19% of the total portfolio. Shares added by 2.56%Hess Corp (HES) - 170,000 shares, 11.57% of the total portfolio. Shares added by 30.77%Noble Energy Inc (NBL) - 200,000 shares, 8.15% of the total portfolio. Southwestern Energy Co (SWN) - 1,360,000 shares, 7.92% of the total portfolio. Shares added by 4.62%Anadarko Petroleum Corp (APC)
• [By Dan Caplinger]

  Friday was a down day on Wall Street, but losses were generally small, and the market closed well above its lowest levels of the session. Initially, investors seemed concerned about further trade tensions between the U.S. and China, but upon further reflection, they appeared to draw comfort from considerable fundamental strength from key sectors of the industrial economy. Even with the overall market recovering from earlier weakness, some stocks still posted substantial declines. Whiting Petroleum (NYSE:WLL), Global Blood Therapeutics (NASDAQ:GBT), and First Solar (NASDAQ:FSLR) were among the worst performers on the day. Here's why they did so poorly.

• [By Logan Wallace]

  Penn Capital Management Co. Inc. purchased a new stake in shares of Whiting Petroleum Corp (NYSE:WLL) in the 1st quarter, HoldingsChannel reports. The fund purchased 318,157 shares of the oil and gas exploration company’s stock, valued at approximately $10,783,000.

• [By Jon C. Ogg]

  Whiting Petroleum Corp. (NYSE: WLL) was reiterated as Overweight and the target price was raised to $56 from $45 (versus a $50.78 close) at KeyBanc Capital Markets.

• [By Logan Wallace]

  Shares of Whiting Petroleum Corp (NYSE:WLL) have been given an average rating of “Buy” by the thirty-two ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation, fifteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $46.58.

Top 5 Oil Stocks To Invest In Right Now: Range Resources Corporation(RRC)

Advisors' Opinion:

• [By Shane Hupp]

  Toronto Dominion Bank increased its holdings in Range Resources Corp. (NYSE:RRC) by 25.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 123,421 shares of the oil and gas exploration company’s stock after purchasing an additional 24,839 shares during the period. Toronto Dominion Bank’s holdings in Range Resources were worth $1,794,000 as of its most recent SEC filing.

• [By Paul Ausick]

  Range Resources Corp. (NYSE: RRC) fell about 3.6% Monday to post a new 52-week low of $14.77 after closing at $15.30 on Friday. The 52-week high is $35.64. Volume of about 9.4 million was about 20% higher than the daily average of around 7.7 million shares traded. The company had no specific news.

• [By Tyler Crowe, Matthew DiLallo, and Reuben Gregg Brewer]

  So we asked three of our investing contributors to each highlight a company they think has a compelling investment case right now in the oil and gas industry. Here's why they selected Devon Energy (NYSE:DVN), Range Resources (NYSE:RRC), and ExxonMobil (NYSE:XOM).

• [By Joseph Griffin]

  Media headlines about Range Resources (NYSE:RRC) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Range Resources earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media headlines about the oil and gas exploration company an impact score of 46.3371462950661 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Snapchat's Still Suffering at the Hands of Instagram

Ever since Instagram rolled out its Stories feature a couple years ago, Snap (NYSE:SNAP) has seen an impact on Snapchat user growth. But it's not just users that prefer Instagram Stories over Snap's -- it's advertisers, too. Ninety percent of marketers prefer advertising on Instagram Stories instead of Snapchat Stories, according to a recent survey from Cowen. That's actually a slight improvement from the beginning of the year.

More importantly, nearly half of all marketers in the survey said they spent less than anticipated on Snapchat ads during the first half of the year. Instagram, meanwhile, saw its spending intentions increase overall among the marketers surveyed.

With 1 billion total monthly users on Instagram, twice as many using Instagram Stories on a daily basis compared to Snapchat, and the power of Facebook (NASDAQ:FB) behind it, Instagram probably isn't done putting pressure on Snap's revenue.

Image source: Instagram.

Stories ads are just getting started

Stories ads are a relatively new format for marketers. Snapchat's only been doing it for two years, and Instagram started offering ads in Stories last March. On Facebook's fourth-quarter earnings call earlier this year, COO Sheryl Sandberg described ads in Stories as "a small but quickly growing part of our revenue."

With Instagram's strong user growth and the relatively low ad load in Stories, there's still a lot of room for Facebook to grow its ad inventory. That's important, as marketers might prefer Instagram for its superior content and targeting capabilities, but will opt for competitors if prices climb too quickly.

Instagram has historically seen between 60% and 67% of its users log into the app daily. That implies over 200 million users are logging into the app, but not clicking on Stories, every day. That's low-hanging fruit for Facebook to convert into additional Stories users. So Instagram can avoid increasing ad load for now if it can encourage more users to click on Stories. It's already taken additional steps to do so, displaying friends' Stories in the middle of the regular feed.

Instagram being in the early stages for ads within Stories is bad news for Snap, which has struggled with engagement in the first half of the year following a botched redesign of the Snapchat app. As long as Instagram continues to expand its ad inventory, that means the preference for Instagram will continue to pressure Snap's top-line growth.

What can Snap do?

Snap isn't going to overcome Instagram's advantages anytime soon. Its best course of action is to do what management says is its only option in a market where products are distributed quickly and freely: innovate.

To that end, Snap has an advantage in augmented reality capabilities, and it's reportedly using it to create visual search capabilities within Snapchat. The new feature would enable users to shop for items they see in the real world simply by pointing their smartphone camera at them. That could potentially enable Snap to do to Instagram what Instagram did to it. Instagram is notably frequently used for shopping.

A visual search product could reinvigorate engagement and open new marketing opportunities for Snap. It's certainly one of the more promising products in Snap's pipeline, as it has real potential to differentiate the company's app from Facebook and other social apps.

But until Snap finds a way to truly differentiate its products -- both consumer-facing and marketer-facing -- it will likely continue to suffer at the hands of Instagram and Facebook.

Buy Federal Bank; target of Rs 120: JM Financial

JM Financial's research report on Federal Bank

Federal Bank reported a strong quarter in 1QFY19, with PAT at INR 2.63bn (+8% above JMFe). The beat in net profit was primarily driven by strong NII growth (+22% YoY), as margins held up for FB. Credit cost was contained at 80bps for FB in 1QFY19, as slippages almost halved sequentially to 2.3% (annualised). Net stress on FB��s loan book (net NPA + other stress) is now at 2% of loans (from 2.3% as of 4QFY18). Management remains confident of containing slippages at INR 11-12bn in FY19E, with credit costs in the range of 65-70bps. Furthermore, FB is positive on its margin outlook, and expects this, along with the containment of credit cost will help it deliver 1% exit RoA by 4QFY19. We remain cautious on the margin outlook for FB and continue to build credit cost of 77bps/74bps in FY19E/FY20E. Our gross slippage expectation of 1.4%/1.2% over FY19E/20E is well below the 2.7% in FY18.

Outlook

We believe FB can deliver RoA/ RoE of 1%/13% in FY20E. Maintain BUY with unchanged TP.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Jul 18, 2018 05:07 pm

Stocks in the news: Karnataka Bank, Ashoka Buildcon, HIL, Chambal Fertilisers, Omaxe

Here are the stocks that are in news today:�

Results Today:�Cyient and Karnataka Bank

Ex-Bonus: Ashoka Buildcon 1:2 and General Insurance 1:1

IDFC: Appoints Rinkoo Somani as interim chief financial officer.

related news Stocks in the news: TCS, Axis Bank, KEC International, IDBI Bank, HFCL, PNB Housing Stocks in the news: HCL Technologies, TCS, IndusInd Bank, Dish TV, SRF, Capital First Stocks in the news: Trigyn Tech, Ashok Leyland, Tata Steel, JP Associates, Fortis

HIL board approves acquisition of German firm through arm

Chambal Fertilisers: Board of directors of Inuva, which is a downstream subsidiary of the company, has approved voluntary winding up of the company under the provisions of Insolvency and Bankruptcy Code. Inuva is not having any business operations.

Sun Pharmaceutical Industries' subisidiary filed lawsuit against Biofrontera Inc. in USA

Fortis Healthcare board to consider fund raising on July 13

Coffee Day Enterprises: Material subsidiary of the company, Coffee Day Global (CDGL) entered into an agreement with UBER Portier.B.V wherein CDGL is partnering with UBER for obtaining technology services through the 'UberEats' mobile application in order to enable distribution of food products. This may help to augment the retail sale and the contract is for a period of five years.

Shree Cement subsidiary completed acquisition of 97.61% stake UCC

MRO-TEK Realty empaneled with Bharat Sanchar Nigam (BSNL) as a national systems integrator partner for enterprise business

Omaxe: Company has executed a Concession Agreement with North Delhi Municipal Corporation (North DMC) for the Redevelopment/Reconstruction of Multi level Car Parking at Gandhi Maidan, Delhi.

Satin Creditcare Network: Board has approved the proposal to transfer MSME business of the company to its wholly owned subsidiary (WOS), acquisition of 11,05,493 equity shares of subsidiary Taraashna Services from MV Mauritius.

Shree Ajit Pulp and Paper received export order of Rs 4.06 crore

Smartlink Network Systems: Company has extinguished equity shares in connection with the buyback of 56 lakh equity shares of Smartlink Holdings.

India Gylcols AGM to be held on August 4

MM Forgings approves to issue bonus shares in 1:1 ratio

IFCI revised its short term benchmark rate from 9% to 9.10% p.a. First Published on Jul 12, 2018 07:39 am

Top 10 Small Cap Stocks To Buy Right Now

tags:FCEL,PQ,ACHN,CNR,

Early on Monday, small cap�Namaste Technologies (OTCMKTS: NXTTF; CNSX: N) announced a Letter of Intent signed between wholly owned subsidiary Cannmart Inc and 7ACRES, a wholly owned subsidiary of Supreme Pharmaceuticals (OTCMKTS: SPRWF; TSXV: FIRE) who will provide Cannmart with a premium range of high quality dried cannabis flower which will be offered in the Company��s medical marketplace.

Supreme is focused on producing high quality cannabis through�curated genetics, quality focused cultivation practices and a post-harvest process that includes a 14-day whole plant drying process and hand finishing of each flower. Under the terms of the LOI, Namaste Technologies has committed to work with Supreme Pharmaceuticals as a preferred vendor as related to possible branded partnerships, in addition to supply for Namaste��s in-house branded medical cannabis, while�all Supreme cannabis will bear the 7ACRES producer��s mark.

Top 10 Small Cap Stocks To Buy Right Now: FuelCell Energy Inc.(FCEL)

Advisors' Opinion:

• [By Peter Graham]

  Small cap fuel cell stock�FuelCell Energy Inc (NASDAQ: FCEL) reported Q4 and fiscal year ended October 31, 2017 earnings�with�Q4 total revenues�being $47.9 million versus $24.5 million:����

• [By Shane Hupp]

  Electro Scientific Industries (NASDAQ: ESIO) and FuelCell Energy (NASDAQ:FCEL) are both small-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

• [By Paul Ausick]

  FuelCell Energy Inc. (NASDAQ: FCEL) posted an increase of 8% in short interest during the two-week period. Some 7.45 million shares were short as of May 31. The stock’s price was $1.76 at Monday’s market close, a spike of about 1.1% for the day, within a 52-week range of $1.08 to $2.49. Shares traded up about 2.5% in the two-week short interest period, and the number of days to cover rose from 14 to 17.

• [By Logan Wallace]

  FuelCell Energy (NASDAQ: FCEL) and HRG Group (NYSE:HRG) are both oils/energy companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

• [By Shane Hupp]

  FuelCell Energy Inc (NASDAQ:FCEL) shares traded up 5.8% on Friday . The stock traded as high as $1.49 and last traded at $1.45. 12,581,855 shares traded hands during trading, an increase of 983% from the average session volume of 1,161,380 shares. The stock had previously closed at $1.37.

Top 10 Small Cap Stocks To Buy Right Now: Petroquest Energy Inc(PQ)

Advisors' Opinion:

• [By Ethan Ryder]

  News headlines about Petroquest Energy (NYSE:PQ) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Petroquest Energy earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the energy company an impact score of 47.638327846877 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Top 10 Small Cap Stocks To Buy Right Now: Achillion Pharmaceuticals Inc.(ACHN)

Advisors' Opinion:

• [By Shane Hupp]

  News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.941587509483 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

• [By Keith Speights]

  Skeptics might deride a comparison of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) as an exercise in finding the biggest loser. Both companies continue to post huge net losses every quarter, and their stocks are down by at least 30% over the last 12 months.

• [By Ethan Ryder]

  Achillion Pharmaceuticals (NASDAQ:ACHN) – Research analysts at B. Riley reduced their FY2018 EPS estimates for shares of Achillion Pharmaceuticals in a research note issued to investors on Wednesday, May 2nd. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will earn ($0.58) per share for the year, down from their previous estimate of ($0.55). B. Riley has a “Neutral” rating and a $3.50 price objective on the stock. B. Riley also issued estimates for Achillion Pharmaceuticals’ FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($0.71) EPS, FY2021 earnings at ($0.70) EPS and FY2022 earnings at ($0.84) EPS.

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Lisa Levin] Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 29.4 percent to $5.50 in pre-market trading after the company disclosed that its first pivotal Phase 3 trial of IV tramadol achieved the primary and key secondary endpoints. MB Financial, Inc. (NASDAQ: MBFI) rose 16.8 percent to $51.00 in pre-market trading. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock. LiveXLive Media, Inc. (NASDAQ: LIVX) rose 9.3 percent to $5.40 in pre-market trading after falling 28.92 percent on Friday. Celyad SA (NASDAQ: CYAD) shares rose 9 percent to $29.30 in pre-market trading after climbing 3.26 percent on Friday. Ethan Allen Interiors Inc. (NYSE: ETH) rose 6.7 percent to $26.40 in pre-market trading after gaining 1.64 percent on Friday. Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) rose 5.4 percent to $3.90 in pre-market trading after gaining 3.06 percent on Friday. Acacia Communications, Inc. (NASDAQ: ACIA) rose 5.2 percent to $34.70 in pre-market trading after gaining 1.38 percent on Friday. Westinghouse Air Brake Technologies Corporation (NYSE: WAB) rose 5.1 percent to $100 in pre-market trading. General Electric Company (NYSE: GE) agreed to merge its transportation unit with Wabtec. Sunrun Inc. (NASDAQ: RUN) shares rose 4.7 percent to $11.50 in pre-market trading. Nasdaq, Inc. (NASDAQ: NDAQ) shares rose 4.3 percent to $93.98 in the pre-market trading session. LaSalle Hotel Properties (NYSE: LHO) shares rose 4.2 percent to $33.25 in pre-market trading. Blackstone Group LP (NYSE: BX) will buy LaSalle Hotel Properties in a $4.8 billion deal, Bloomberg reported. Monro, Inc. (NASDAQ: MNRO) shares rose 4 percent to $58.35 in pre-market trading as the company posted upbeat quarterly earnings and disclosed that it has acquired Free Service Tire. HUYA Inc. (NYSE: HUYA) rose 3.7 percent to $19.75 in pre-market trading after falling 4.80 percent on Friday.

  Find out what's going

Top 10 Small Cap Stocks To Buy Right Now: China Metro-Rural Holdings Limited(CNR)

Advisors' Opinion:

• [By Ethan Ryder]

  State of Tennessee Treasury Department lessened its stake in shares of Canadian National Railway (NYSE:CNI) (TSE:CNR) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 842,775 shares of the transportation company’s stock after selling 13,507 shares during the quarter. State of Tennessee Treasury Department owned about 0.11% of Canadian National Railway worth $61,565,000 as of its most recent filing with the SEC.

• [By Joseph Griffin]

  Shares of Canadian National Railway (TSE:CNR) (NYSE:CNI) have been given an average recommendation of “Buy” by the eleven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is C$109.36.

• [By Max Byerly]

  Canadian National Railway (NYSE:CNI) (TSE:CNR) – Cormark raised their Q3 2018 earnings per share (EPS) estimates for Canadian National Railway in a research report issued to clients and investors on Tuesday, April 10th. Cormark analyst D. Tyerman now expects that the transportation company will post earnings per share of $1.15 for the quarter, up from their previous estimate of $1.14.

• [By Shane Hupp]

  Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp cut its position in Canadian National Railway (NYSE:CNI) (TSE:CNR) by 21.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,956,400 shares of the transportation company’s stock after selling 522,300 shares during the period. Canadian National Railway accounts for about 1.7% of Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s investment portfolio, making the stock its 7th biggest position. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp owned 0.27% of Canadian National Railway worth $184,215,000 at the end of the most recent reporting period.

Best Biotech Stocks To Own Right Now

tags:BIIB,ALNY,AMGN,ARQL,

Achaogen (NASDAQ:AKAO) is a clinical-stage biotechnology company specializing in creating antibiotics to treat MDR (multidrug resistant) bacteria. Its lead candidate, plazomicin, recently was recommended for approval for cUTI (complicated urinary tract infections) on May 2 by an FDA advisory committee. This almost guarantees the FDA will approve the drug for marketing, but the stock price dropped rather dramatically (Achaogen down 26% premarket after Ad Com vote).

The fall was because the committee did not recommend plazomicin for treating bloodstream infections. This brought into question how broadly applicable plazomicin might become. Typically, after receiving the first FDA approval in an indication, companies seek label expansion (approval in other indications) by submitting further trial data. The long-term value of a company may vary greatly by how broadly applicable a commercial drug is.

The situation is similar to the situation for another company, Tetraphase (NASDAQ:TTPH), which has been developing a rival drug, with a very different mechanism of action, to treat MDR infections. In the Tetraphase case Phase 3 data for cUTI failed to reach the expected endpoint, but the drug appears on track for a likely approval for treating cIAI (complicated intra-abdominal infections), with a decision due towards the end of August.

Best Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Brian Orelli]

  Data source: Ionis Pharmaceuticals.

  What happened with Ionis Pharmaceuticals this quarter? Revenue increased thanks to $41 million in royalties from Biogen's (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis' financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.

  Image source: Getty Images.

• [By Brian Orelli]

  Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earnings�increase in the first quarter. While revenue growth wasn't as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren't a sign of future trouble.

• [By Garrett Baldwin]
  Markets are keeping a close eye on the 10-year bond, which is hovering near 3% – an important psychological level that is likely to influence future price movements. On Monday, Fox Business Network's "Varney & Co." asked Money Morning Chief Investment Strategist Keith Fitz-Gerald if investors should be worried. Here's what Keith had to say about the 10-year Treasury yield… and how it will affect your stocks and bonds in the future. The price of Brent crude oil topped $75.00 and hit its highest level since November 2014. Oil traders were eyeing the ongoing efforts of OPEC and Russia to reduce excessive production around the globe, rising demand ahead of peak driving season, and the possibility that the Trump administration will slap Iran with a new round of sanctions. Three Stocks to Watch Today: KO, GOOGL, SLM Shares of The Coca-Cola Co.�(NYSE: KO) added 1.2% after the firm easily beat earnings and revenue expectations. The firm cited strong demand for its new flavors of Diet Coke and its Coke Zero Sugar. Demand was so strong for the quarter that the firm reported organic sales growth of 5%. The company reported earnings per share of $0.47, topping estimates by a penny. Revenue of $7.6 billion easily beat Wall Street estimates. Shares of Alphabet Inc. (Nasdaq: GOOGL) seesawed in pre-market hours. The online search giant topped Wall Street earnings and revenue expectations after the bell Monday. However, shares were off 0.5% after executives announced that its business costs were on the rise. The firm's real estate and computer purchases tripled in one year, to $7.3 billion. About one-third of that total came from its $2.4 billion purchase of the Chelsea Market building in New York City. Good news for SLM Corp.�(NYSE: SLM) investors, but bad news for indebted college students and graduates. The firm – also known as Sallie Mae – topped Wall Street earnings expectations on Monday. The firm said that it increased its loan o
• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.86 million shares from the previous 3.45 million. The stock recently traded at $287.00, within a 52-week range of $244.28 to $370.57.

• [By Shannon Jones]

  In this week's episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte's Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis' (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB)�might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.

• [By Sean Williams, Chuck Saletta, and Brian Feroldi]

  As noted, the ability to take numerous swings for the fence makes Ionis special. It's often a marvel when a mid-cap drugmaker has a half-dozen experimental drugs, let alone one working with 25. Spinal muscular atrophy drug Spinraza, which was licensed to Biogen (NASDAQ:BIIB), is one such drug that's put Ionis and its antisense technology on the map. Last year, Spinraza netted "just" $882 million in total sales, but delivered $364 million globally in the first quarter of 2018. That extrapolates out to more than $1.4 billion, which means added royalty revenue for Ionis.

Best Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Joseph Griffin]

  BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

• [By Keith Speights]

  I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

• [By Brian Orelli]

  The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn't think a few months will really matter: "We don't really feel that's going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we're very well prepared to be ready to launch following approval."

Best Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Cory Renauer]

  Patient Amgen Inc.�(NASDAQ:AMGN) shareholders have seen the stock quadruple in price over the past decade, plus they've enjoyed one of the fastest-growing dividends in biopharma. Now that the company's launched a new migraine headache drug, investors are wondering if the former highflier can put on another memorable performance.

• [By ]

  This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days," according to Real Money Pro columnist Bret Jensen.

• [By Logan Wallace]

  Shares of Amgen (NASDAQ:AMGN) have earned an average recommendation of “Hold” from the twenty-seven research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and ten have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $193.19.

Best Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Stephan Byrd]

  ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

• [By Ethan Ryder]

  ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

• [By Joseph Griffin]

  ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

Intelligent Investment Chain Price Reaches $0.0032 (IIC)

Intelligent Investment Chain (CURRENCY:IIC) traded up 1.3% against the dollar during the 1-day period ending at 20:00 PM ET on July 4th. One Intelligent Investment Chain token can currently be purchased for $0.0032 or 0.00000049 BTC on popular cryptocurrency exchanges including BCEX and Lbank. Over the last week, Intelligent Investment Chain has traded 7.8% higher against the dollar. Intelligent Investment Chain has a market capitalization of $0.00 and approximately $428,914.00 worth of Intelligent Investment Chain was traded on exchanges in the last 24 hours.

Here is how other cryptocurrencies have performed over the last 24 hours:

Get Intelligent Investment Chain alerts: Ripple (XRP) traded 4.6% lower against the dollar and now trades at $0.45 or 0.00007633 BTC. Stellar (XLM) traded up 2.3% against the dollar and now trades at $0.21 or 0.00003206 BTC. IOTA (MIOTA) traded up 5% against the dollar and now trades at $1.18 or 0.00018113 BTC. Tether (USDT) traded up 0.1% against the dollar and now trades at $1.00 or 0.00015280 BTC. NEO (NEO) traded up 12.4% against the dollar and now trades at $40.30 or 0.00616009 BTC. TRON (TRX) traded up 0.9% against the dollar and now trades at $0.0387 or 0.00000591 BTC. Binance Coin (BNB) traded down 1% against the dollar and now trades at $13.96 or 0.00213468 BTC. VeChain (VET) traded 1.4% higher against the dollar and now trades at $2.67 or 0.00040742 BTC. Ontology (ONT) traded up 0.5% against the dollar and now trades at $5.06 or 0.00077415 BTC. Zilliqa (ZIL) traded up 16.3% against the dollar and now trades at $0.0900 or 0.00001376 BTC.

Intelligent Investment Chain Token Profile

Intelligent Investment Chain’s total supply is 21,000,000,000 tokens. Intelligent Investment Chain’s official Twitter account is @iichain. Intelligent Investment Chain’s official message board is medium.com/@iichain. Intelligent Investment Chain’s official website is www.iicoin.io.

Intelligent Investment Chain Token Trading

Intelligent Investment Chain can be traded on the following cryptocurrency exchanges: BCEX and Lbank. It is usually not possible to purchase alternative cryptocurrencies such as Intelligent Investment Chain directly using US dollars. Investors seeking to acquire Intelligent Investment Chain should first purchase Ethereum or Bitcoin using an exchange that deals in US dollars such as GDAX, Gemini or Changelly. Investors can then use their newly-acquired Ethereum or Bitcoin to purchase Intelligent Investment Chain using one of the aforementioned exchanges.

Zacks: Analysts Expect Cardlytics Inc (CDLX) to Announce -$0.40 Earnings Per Share

Wall Street analysts forecast that Cardlytics Inc (NASDAQ:CDLX) will announce earnings of ($0.40) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Cardlytics’ earnings, with the lowest EPS estimate coming in at ($0.48) and the highest estimate coming in at ($0.32). The business is expected to issue its next earnings results on Thursday, August 9th.

According to Zacks, analysts expect that Cardlytics will report full-year earnings of ($1.47) per share for the current year, with EPS estimates ranging from ($1.68) to ($1.25). For the next financial year, analysts anticipate that the firm will post earnings of ($0.58) per share, with EPS estimates ranging from ($0.90) to ($0.25). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Cardlytics.

Get Cardlytics alerts:

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Thursday, May 10th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.62) by $0.02. The business had revenue of $32.71 million during the quarter, compared to analysts’ expectations of $29.74 million.

Several brokerages have weighed in on CDLX. JPMorgan Chase & Co. began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set an “overweight” rating and a $23.00 price target for the company. KeyCorp began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set an “overweight” rating and a $23.00 price target for the company. Wells Fargo & Co began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set an “outperform” rating and a $22.00 price target for the company. Bank of America began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set a “neutral” rating and a $19.00 price target for the company. Finally, SunTrust Banks began coverage on shares of Cardlytics in a research report on Tuesday, March 6th. They set a “buy” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $22.40.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System purchased a new stake in Cardlytics during the 1st quarter valued at $122,000. California Public Employees Retirement System purchased a new stake in shares of Cardlytics in the 1st quarter worth about $146,000. Frontier Capital Management Co. LLC purchased a new stake in shares of Cardlytics in the 1st quarter worth about $148,000. Spark Investment Management LLC purchased a new stake in shares of Cardlytics in the 1st quarter worth about $150,000. Finally, Barclays PLC purchased a new stake in shares of Cardlytics in the 1st quarter worth about $175,000. 48.32% of the stock is owned by institutional investors and hedge funds.

CDLX traded down $0.54 during trading on Wednesday, hitting $21.28. 69,244 shares of the stock traded hands, compared to its average volume of 156,419. The stock has a market capitalization of $442.16 million and a P/E ratio of -2.65. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.81. Cardlytics has a 12-month low of $11.10 and a 12-month high of $25.71.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com